SCHEMBL3972368

SCHEMBL3972368

[CH2]c1cccc2[nH]c(C)nc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.53
ALDH1A1 P00352 1/20 0.43
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADRB2 P07550 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MGAM O43451 6/20 0.38
GAA P10253 6/20 0.38
SI P14410 6/20 0.38
MGAM2 Q2M2H8 6/20 0.38
DHODH Q02127 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3962251 0.79 ALOX15 (0.37) PARP1ALDH1A1CYP2D6CYP2C19MGAM
SCHEMBL20936149 0.79 PARP1 (0.56) PARP1ALDH1A1DRD2DRD4DRD3
SCHEMBL353891 0.79 PARP1 (0.56) PARP1MGAMGAASIMGAM2
Bromide SCHEMBL5318091 0.78 PARP1 (0.55) PARP1MGAMGAASIMGAM2
SCHEMBL1902643 0.76 PARP1 (0.53) PARP1ALDH1A1DRD2DRD4DRD3
SCHEMBL979914 0.76 NUDT1 (0.51) ALDH1A1GAA
SCHEMBL3973619 0.76 NPC1 (0.50) PARP1ALDH1A1ADORA3HTTKDM4E
SCHEMBL1013125 0.76 PARP1 (0.59) PARP1ALDH1A1DRD2DRD4DRD3
SCHEMBL29438962 0.76 PARP1 (0.53) PARP1ALDH1A1DRD2DRD4DRD3
SCHEMBL1701339 0.76 PARP1 (0.53) PARP1ALDH1A1DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
US-6884806-B2 Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-26 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
WO-2003031431-A1 CYCLIC SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$G(A) CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 PARP1 399/4885ALDH1A1 839/4885DRD2 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.